Author丨Lin Yunxiao
Editor丨Xu Xu
On 26 April, the Ninth Session of the Standing Committee of the 14th National People's Congress (NPC) adopted the report of the Qualifications Committee of the 14th NPC Standing Committee on the qualifications of individual deputies.
Among them, Yang Xiaoming, a deputy to the 14th National People's Congress elected by the Tibet Autonomous Region, a member of the Ethnic Committee of the 14th National People's Congress, and the former chief engineer and chief scientist of China National Pharmaceutical Group Co., Ltd., was suspected of serious violations of discipline and law, and on March 29, 2024, the ninth meeting of the Standing Committee of the 12th National People's Congress of the Tibet Autonomous Region decided to remove Yang Xiaoming from his position as a deputy to the 14th National People's Congress.
This is also the first official disclosure that Yang Xiaoming is suspected of serious violations of discipline and law.
According to public information, Yang Xiaoming was born in February 1962, a native of Zhouqu County, Gansu Province, and an expert in biological products. In 1980, he was admitted to the Department of Clinical Medicine, School of Medicine, Lanzhou University, and was assigned to the Lanzhou Institute of Biological Products after graduation. In 1997, Yang Xiaoming went to the National Institutes of Health (NIH) to engage in research on molecular microbiology and vaccinology. In 2002, Yang Xiaoming returned to China to serve as the executive deputy director of Wuhan Institute of Biological Products.
Since 2010, Yang Xiaoming has worked at China National Biotechnology Co., Ltd., a subsidiary of Sinopharm Group. Yang Xiaoming used to be the director of the National United Vaccine Engineering Technology Research Center, the chief scientist of the national "863" program vaccine project, and the chairman of China Biologics.
According to public reports, Yang Xiaoming has focused on basic research on the application of infectious disease vaccines, the creation of engineering technology systems and the creation of major products for nearly 40 years, and has been committed to infectious disease vaccine innovation for a long time. Yang Xiaoming has led the team to develop and market the national first-class new drug poliovirus inactivated vaccine, and has also broken through the bottleneck technology of acellular pertussis vaccine, and successfully developed and marketed the country's first acellular diphtheria-pertussis combined vaccine.
During the new crown epidemic, Yang Xiaoming led Sinopharm China Biologics to achieve significant results in vaccine research and development. Under his leadership, at the beginning of the outbreak, the Chinese biological tissue technical team developed a new coronavirus genetic diagnostic kit in only 48 hours, which was first recommended by the National Center for Disease Control and Prevention for use in Wuhan Hospital, Hubei Province, and the first batch was approved by the State Food and Drug Administration.
In January 2020, it also took the lead in proposing and developing convalescent plasma and specific immunoglobulin therapy for patients who have recovered from new coronary pneumonia. Sinopharm China Biologics' inactivated vaccine was first approved for emergency use, and a phase III clinical study was launched, and on December 30, 2020, it was approved by the National Medical Products Administration for conditional marketing. Yang Xiaoming also won the title of "National Advanced Individual in Fighting the New Coronary Pneumonia Epidemic".
According to the official website of Sinopharm Group, Sinopharm Group has a whole industrial chain of scientific and technological research and development, industrial manufacturing, logistics and distribution, retail chain, medical health, engineering technology, professional exhibition, international operation, and financial investment. The company's operating income exceeds 700 billion yuan, ranking 80th among the world's top 500 companies and first among global pharmaceutical companies.
At present, Sinopharm Group has more than 1,700 member companies, including 9 listed companies, including Sinopharm Group, Sinopharm Co., Ltd., Sinopharm Accord, Tiantan Biologics, China Traditional Chinese Medicine, Sinopharm Modern, Sinopharm Taiji, Jiuqiang Biotechnology and Weiguang Biotech, with a total of 230,000 employees.
This time, Yang Xiaoming is suspected of serious violations of discipline and law, and this is not the first time that senior executives of Sinopharm Group have been investigated this year. On January 31, 2024, according to the Discipline Inspection and Supervision Group of the Central Commission for Discipline Inspection and the State Supervision Commission in the State-owned Assets Supervision and Administration Commission of the State Council and the Liaoning Provincial Commission for Discipline Inspection and Supervision, Zhou Bin, former member of the Party Committee and Deputy General Manager of Sinopharm Group, and former Secretary of the Party Committee and Chairman of Shanghai Modern Pharmaceutical Co., Ltd., is suspected of serious violations of discipline and law, and is currently undergoing disciplinary review and supervision investigation by the Discipline Inspection and Supervision Group of the Central Commission for Discipline Inspection and the State Supervision Commission in the State-owned Assets Supervision and Administration Commission of the State Council and the Huludao Municipal Supervision Commission of Liaoning Province.
Since the beginning of 2024, medical insurance, health care, discipline inspection commissions, auditing, market supervision and management and other departments have sent a clear signal that the medical anti-corruption action will continue. Especially in April, the Central Commission for Discipline Inspection released a number of articles pointing at medical corruption.
On April 25, the official website of the Central Commission for Discipline Inspection published an article "Secretary Talks| Constantly eradicate the soil and conditions that breed corruption". It is pointed out that the use of information technology to empower and increase the efficiency of power supervision, improve the linkage mechanism of corruption early warning, for state-owned enterprises, agriculture, education, medical care, rural revitalization and other key areas, through information comparison to achieve automatic early warning, promote the supervision of the threshold forward, timely discovery and investigation of the exercise of power irregular, incorruptible and other problems.
Previously, on April 16, the Central Commission for Discipline Inspection released an article "Forward | A clue has found a string of "big rats", revealing the details of the investigation and handling of corruption cases in the medical system. According to the article, the personnel of the Guilin Municipal Commission for Discipline Inspection and Supervision of Guangxi Province found that a medical device manufacturer involved in the case and Tang Moumou, then secretary of the Party Committee of Guilin Hospital of Integrated Traditional Chinese and Western Medicine, were likely to have improper economic dealings through a bank flow information. The case-handling personnel found that Tang's bank account flow was very abnormal, and there were hundreds of thousands of yuan or even millions of yuan in income and expenditure every month.
Taking this as a breakthrough, the task force talked to the medical device manufacturer to understand the situation. The medical device manufacturer not only confessed to the improper economic dealings between him and Tang, but also confessed the fact that he had offered bribes to a number of leading cadres of the hospital. In May 2019, Tang Moumou was taken into custody. After investigation, Tang Moumou took advantage of his position to seek benefits for suppliers in the procurement of drugs, consumables, and medical devices, and accepted huge bribes.
On April 11, the Central Commission for Discipline Inspection issued an article "Theoretical Vision丨 Create a Clean and Positive Pharmaceutical Industry Ecology", which also mentioned that it is necessary to pay close attention to the "key minority" such as leading cadres and key positions such as drug consumables, equipment procurement, inspection and inspection, administrative logistics, etc., and promptly remind and correct and plug loopholes when emerging and tendentious problems are found.
It is necessary to strengthen the combing and collective research and judgment of problem clues, comprehensively doxx the clues of stock problems in the field of medicine, improve the quality and efficiency of the work of discipline inspection and supervision institutions in combination with the implementation of "one school, one policy", cooperate with the requirements of centralized rectification tasks, further promote the clean-up of backlogs, participate in the verification team, implement ledger management, and supervise the listing;
SFC
Editor: Jiang Peipei, intern: Huang Lihong
Too suddenly! A bank was shut down
Vanke's urgent response: resolutely opposed
Is there any pressure on the Xiaomi SU7 to be listed?
